SR9009 vs SR9011: REV-ERB Agonist Comparison for Research

Quick Answer

Key difference in one line: SR9009 and SR9011 are both synthetic REV-ERBα/β agonists characterised in the same foundational paper (Solt et al. 2012, Nature). SR9011 has higher lipophilicity and greater CNS penetration in preclinical models. SR9009 is more widely studied for peripheral metabolic pathway research. Neither is FDA-approved for any use.

Researchers looking to buy SR9009 for laboratory investigation can source it as a research-grade compound at BehemothLabz. All products are independently third-party tested, with COA available per batch. Sold strictly for laboratory research only.

Disclaimer: SR9009 and SR9011 is a research compound not approved by the U.S. FDA for any use. Strictly for laboratory research only.

What Are SR9009 and SR9011?

SR9009 and SR9011 are synthetic pyrrole derivatives that act as selective agonists of the nuclear receptors REV-ERBα and REV-ERBβ — key components of the core circadian clock mechanism. They were first characterised as a pair in Solt et al. (2012, Nature). REV-ERB nuclear receptors link circadian rhythm timing to metabolic gene regulation in preclinical models. Neither compound is FDA-approved for any use, and both are supplied strictly for laboratory research.

Mechanistic Comparison

Target receptors: Both SR9009 and SR9011 are REV-ERBα and REV-ERBβ agonists. EC50 values documented in Solt et al. 2012: SR9009 ~670 nM (REV-ERBα), SR9011 ~800 nM (REV-ERBβ).

Lipophilicity: SR9011 has higher lipophilicity than SR9009 in published preclinical data, associated with greater CNS penetration in rodent model studies.

Peripheral metabolic data: SR9009 is more extensively characterised in peripheral metabolic pathway studies (liver, skeletal muscle, adipose tissue) in published preclinical literature.

CNS penetration: SR9011 is the preferred probe compound for CNS REV-ERB research due to documented superior brain exposure in rodent pharmacokinetic studies.

Metabolic gene targets: Both: BMAL1, CLOCK, CRY, PER (circadian genes). Downstream: CPT-1b, PGC-1α (fatty acid oxidation). Skeletal muscle mitochondrial biogenesis (Woldt et al. 2013, documented specifically for REV-ERBα).

Route in published studies: Both characterised primarily via intraperitoneal (IP) injection in published preclinical data (Solt et al. 2012: 100 mg/kg IP, twice daily). Oral bioavailability data are limited in the published literature.

Critical Research Data Limitations

Dierickx et al. (2019, PNAS) documented that SR9009 exerts REV-ERB-independent effects on cell proliferation, metabolism, and gene transcription in two cell types depleted of REV-ERBs. This is a mandatory disclosure for any SR9009 or SR9011 research programme: effects cannot be exclusively attributed to REV-ERB agonism, and experimental designs must account for REV-ERB-independent pathways when interpreting results.

Oral bioavailability limitation: The foundational Solt et al. 2012 study used IP injection at 100 mg/kg twice daily. Efficacy via oral administration has not been established in published peer-reviewed literature. Researchers designing oral administration studies must account for this data gap.

Risks and Limitations of SR9009 / SR9011 Research

Mandatory reading before working with this compound in any laboratory setting.

REV-ERB-Independent Effects

Dierickx et al. (2019, PNAS) documented REV-ERB-independent effects of SR9009 on proliferation, metabolism, and gene transcription. Study designs must not assume all observed effects are REV-ERB-mediated.

Route Limitation

Published preclinical efficacy data use IP injection. Oral bioavailability is not established in peer-reviewed literature. Design studies accordingly.

Handling Precautions

Both compounds should be handled by trained laboratory personnel. Use appropriate PPE. Verify COA per batch before use.

Storage

Store at room temperature in a dry, sealed environment away from light and moisture.

Data Limitations

SR9009 and SR9011 have not completed any clinical development programme. All efficacy and safety data derive from in vitro and rodent preclinical studies only.

Conclusion

SR9009 and SR9011 are both synthetic REV-ERBα/β agonists, characterised together in Solt et al. (2012, Nature). SR9011's higher lipophilicity gives it superior CNS penetration in preclinical models, making it the preferred probe for CNS REV-ERB research. SR9009 has a more extensive peripheral metabolic pathway characterisation in published literature. A critical finding from Dierickx et al. (2019, PNAS) — that SR9009 exerts REV-ERB-independent effects — is mandatory disclosure for any research programme involving these compounds. Neither is approved for any use.

SR9009 is available for sale at BehemothLabz for licensed laboratory research use only. Each batch is independently third-party tested, and a Certificate of Analysis (COA) is available per batch. Not for any other use.

FAQs

What is the key difference between SR9009 and SR9011 in preclinical models?

SR9011 has higher lipophilicity and superior CNS penetration in preclinical pharmacokinetic data. SR9009 has a more extensive peripheral metabolic pathway characterisation. Both are REV-ERBα/β agonists with similar EC50 values documented in Solt et al. 2012.

Are SR9009 effects exclusively due to REV-ERB agonism?

No. Dierickx et al. (2019, PNAS) documented REV-ERB-independent effects of SR9009 on proliferation, metabolism, and gene transcription in cells depleted of REV-ERBs. This is a mandatory consideration for any study design.

Was the original SR9009 data from oral or injected administration?

The foundational Solt et al. 2012 Nature paper used IP injection at 100 mg/kg twice daily in mice. Oral bioavailability efficacy data are not established in peer-reviewed published literature.

Where can I buy SR9009 for research?

BehemothLabz offers SR9009 for sale for laboratory research purposes only. Each batch is independently third-party tested, with a COA available per batch.

⚠ ATTENTION — BehemothLabz Research Compound Notice

All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. Not for any other use. Contact support@behemothlabz.com with any concerns.

References

•       Solt LA, Wang Y, Banerjee S, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012;485(7396):62–68. https://pubmed.ncbi.nlm.nih.gov/22460906/
•       Woldt E, Sebti Y, Solt LA, et al. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nature Medicine. 2013;19(8):1039–1046. https://pubmed.ncbi.nlm.nih.gov/23892171/